Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Share-based Compensation (2021 - 2025)

SAB Biotherapeutics (SABS) has disclosed Share-based Compensation for 5 consecutive years, with $3.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Share-based Compensation rose 370.19% year-over-year to $3.2 million, compared with a TTM value of $5.2 million through Dec 2025, up 77.12%, and an annual FY2025 reading of $5.2 million, up 77.12% over the prior year.
  • Share-based Compensation was $3.2 million for Q4 2025 at SAB Biotherapeutics, up from $800764.0 in the prior quarter.
  • Across five years, Share-based Compensation topped out at $3.2 million in Q4 2025 and bottomed at -$459250.0 in Q2 2023.
  • Average Share-based Compensation over 5 years is $819213.1, with a median of $627198.0 recorded in 2025.
  • The sharpest move saw Share-based Compensation tumbled 180.59% in 2023, then surged 370.19% in 2025.
  • Year by year, Share-based Compensation stood at $651472.0 in 2021, then decreased by 3.52% to $628539.0 in 2022, then skyrocketed by 262.78% to $2.3 million in 2023, then plummeted by 70.44% to $674135.0 in 2024, then soared by 370.19% to $3.2 million in 2025.
  • Business Quant data shows Share-based Compensation for SABS at $3.2 million in Q4 2025, $800764.0 in Q3 2025, and $627198.0 in Q2 2025.